UBC Okanagan is teaming up with a Vancouver Island-based producer of medical marijuana to host Canada’s first clinical trial studying the effects of treating PTSD with the drug.
“Research suggests that PTSD affects over nine per cent of men and women in Canada, and many more worldwide,” said Trev Bungay, vice-president of Trauma Healing Centers. “Treatment is necessary in order to help those who have served their country or experienced an unfortunate traumatic event find coping methods or continue to live a full and normal life.”
The clinical trial, in partnership with Nanaimo-based Tilray, has been approved by Health Canada and will begin this month.
